{"id":505850,"date":"2020-09-08T13:24:02","date_gmt":"2020-09-08T13:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=505850"},"modified":"2020-09-08T13:24:02","modified_gmt":"2020-09-08T13:24:02","slug":"lag3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lag3next-generation-immunotherapy-competitive-landscape-and-market-forecast-2035-by-delveinsight_505850.html","title":{"rendered":"LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035 by DelveInsight"},"content":{"rendered":"
\"LAG-3-Next<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018LAG-3-Next Generation Immunotherapy\u2014Competitive Landscape and Market Forecast\u20132035\u2019 report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

DelveInsight’s ‘LAG-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035’<\/strong><\/a> report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

The report provides the upcoming drugs, market share of this target by indications, forecasted market size of LAG-3-Next Generation Immunotherapy from 2022 to 2035 segmented by seven major markets. This report discusses the recent findings on LAG-3, the role it plays in regulating immune responses in different cell types and the rationale for targeting LAG-3 for effective cancer immunotherapy. The report also covers the current scenario, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n

Geography Covered<\/strong><\/p>\n

• The United States<\/p>\n

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)<\/p>\n

• Japan<\/p>\n

Study Period: 2022–2035<\/strong><\/p>\n

View report: https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape<\/a><\/strong><\/p>\n

LAG-3-Next Generation Immunotherapy Understanding<\/strong><\/p>\n

Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the “fifth pillar” of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI which has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 have achieved durable responses in melanoma, renal cancer, Hodgkin’s diseases and lung cancer. However, the success rate of these treatments has been low and a large number of cancers, including colorectal cancer remain largely refractory to CTLA-4 and PD-1 blockade.<\/p>\n

Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. T cells are a type of white blood cell that are part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1. It acts by regulating CD8+ Tcell expansion in immune reactions that have already been initiated (inhibitory signal) and also, by increasing the Treg cell activity.<\/p>\n

LAG-3-Next Generation Immunotherapy Drug Chapters<\/strong><\/p>\n

This segment of the LAG-3-Next Generation Immunotherapy<\/strong><\/a> report encloses the detailed analysis of late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the indication-specific clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and awards, advantages and disadvantages of each included drug, and the latest news and press releases.<\/p>\n

The major key players such as MacroGenics\/Zai Lab, Bristol-Myers Squibb\/Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, Regeneron, Xencor, Incyte Biosciences\/Agenus, Roche, GlaxoSmithKline, Innovent Biologics (Suzhou) Co. Ltd. and others will significantly increase the market during the forecast period (2022–2035).  <\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape<\/a><\/strong><\/p>\n

Scope of the report<\/strong><\/p>\n

• The report covers the descriptive overview of LAG-3-Next Generation Immunotherapy, explaining its pathophysiology, and current trends in the research.<\/p>\n

• Additionally, an all-inclusive account of emerging therapies for LAG-3-Next Generation Immunotherapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.<\/p>\n

• A detailed review of LAG-3-Next Generation Immunotherapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.<\/p>\n

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the LAG-3-Next Generation Immunotherapy market.<\/p>\n

Table of contents:<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary<\/p>\n

3. Competitive Intensity of LAG-3-Next Generation Immunotherapy<\/p>\n

4. Market Competition of LAG-3-Next Generation Immunotherapy<\/p>\n

5. Technological innovations in LAG-3-Next Generation Immunotherapy<\/p>\n

6. Multivariate analysis of the key players in LAG-3-Next Generation Immunotherapy<\/p>\n

7. LAG-3-Next Generation Immunotherapy Market Overview at a Glance<\/p>\n

7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035<\/p>\n

8. Pipeline Therapeutics Analysis (Active Products)<\/p>\n

9. Overview: Next Generation Immunotherapy<\/p>\n

9.1. Immune Checkpoint Inhibitors<\/p>\n

9.2. LAG-3<\/p>\n

10. Future Prospects and Challenges in LAG-3-Next Generation Immunotherapy<\/p>\n

10.1. Current Clinical Challenges in Immunotherapies<\/p>\n

10.2. Future direction of improving response rates of Immunotherapy<\/p>\n

11. SWOT Analysis<\/p>\n

12. Epidemiology and Forecasting Assumptions<\/p>\n

13. Emerging Drugs<\/p>\n

13.1. Target indications of LAG-3<\/p>\n

13.2. MGD013: MacroGenics\/Zai Lab<\/p>\n

13.2.1. Drug Description<\/p>\n

13.2.2. Other Developmental Activities<\/p>\n

13.2.3. Clinical Development<\/p>\n

13.2.4. Product Profile<\/p>\n

13.3. MBG453: Novartis<\/p>\n

13.3.1. Product Description<\/p>\n

13.3.2. Other Developmental Activities<\/p>\n

13.3.3. Clinical Development<\/p>\n

13.3.4. Product Profile<\/p>\n

13.4. Relatlimab: Bristol-Myers Squibb\/Ono Pharmaceuticals<\/p>\n

13.4.1. Product Description<\/p>\n

13.4.2. Other Developmental Activities<\/p>\n

13.4.3. Clinical Development<\/p>\n

13.4.4. Product Profile<\/p>\n

13.5. Eftilagimod Alpha (IMP321): Immutep<\/p>\n

13.5.1. Drug Description<\/p>\n

13.5.2. Clinical Development<\/p>\n

13.5.3. Product Profile<\/p>\n

13.6. LAG525: Novartis<\/p>\n

13.6.1. Product Description<\/p>\n

13.6.2. Other Developmental Activities<\/p>\n

13.6.3. Clinical Development<\/p>\n

13.6.4. Product Profile<\/p>\n

13.7. MK-4280: Merck<\/p>\n

13.7.1. Product Description<\/p>\n

13.7.2. Other Developmental Activities<\/p>\n

13.7.3. Clinical Development<\/p>\n

13.7.4. Product Profile<\/p>\n

13.8. REGN3767: Regeneron<\/p>\n

13.8.1. Product Description<\/p>\n

13.8.2. Other Developmental Activities<\/p>\n

13.8.3. Clinical Development<\/p>\n

13.8.4. Product Profile<\/p>\n

13.9. FS118: F-star Therapeutics<\/p>\n

13.9.1. Product Description<\/p>\n

13.9.2. Other Developmental Activities<\/p>\n

13.9.3. Clinical Development<\/p>\n

13.9.4. Product Profile<\/p>\n

13.10. XmAb22841: Xencor<\/p>\n

13.10.1. Product Description<\/p>\n

13.10.2. Other Developmental Activities<\/p>\n

13.10.3. Clinical Development<\/p>\n

13.10.4. Product Profile<\/p>\n

13.11. INCAGN2385: Incyte Biosciences\/Agenus<\/p>\n

13.11.1.  Product Description<\/p>\n

13.11.2.  Other Developmental Activities<\/p>\n

13.11.3.  Clinical Development<\/p>\n

13.11.4.  Product Profile<\/p>\n

13.12. RO7247669: Roche<\/p>\n

13.12.1.  Product Description<\/p>\n

13.12.2.  Other Developmental Activities<\/p>\n

13.12.3.  Clinical Development<\/p>\n

13.12.4.  Product Profile<\/p>\n

13.13. TSR-033: GlaxoSmithKline<\/p>\n

13.13.1.  Product Description<\/p>\n

13.13.2.  Other Developmental Activities<\/p>\n

13.13.3.  Clinical Development<\/p>\n

13.13.4.  Product Profile<\/p>\n

13.14. IBI110: Innovent Biologics (Suzhou) Co. Ltd.<\/p>\n

13.14.1.  Product Description<\/p>\n

13.14.2.  Other Developmental Activities<\/p>\n

13.14.3.  Clinical Development<\/p>\n

13.14.4.  Product Profile<\/p>\n

14. Assessment by Indication<\/p>\n

15. Assessment by Route of Administration<\/p>\n

16. Assessment by Stage and Indication<\/p>\n

17. Assessment by stage and Route of Administration<\/p>\n

18. LAG-3-7 Major Market Analysis<\/p>\n

18.1. Market Outlook in the 7MM<\/p>\n

18.1.1. Total Market size of LAG-3 in 7MM<\/p>\n

18.1.2. Market Size of LAG-3 by indication in 7MM<\/p>\n

19. Market Drivers<\/p>\n

20. Market Barriers<\/p>\n

21. Appendix<\/p>\n

21.1. Report Methodology<\/p>\n

22. DelveInsight Capabilities<\/p>\n

23. Disclaimer<\/p>\n

24. About DelveInsight<\/p>\n

Download report: https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape<\/a><\/strong><\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

Contact us:<\/strong>
Shruti Thakur<\/strong>
info@delveinsight.com<\/strong>
+919650213330<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018LAG-3-Next Generation Immunotherapy\u2014Competitive Landscape and Market Forecast\u20132035\u2019 report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-505850","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/505850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=505850"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/505850\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=505850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=505850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=505850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}